Current Research and Scholarly Interests
Working as a clinical nephrologist in my native Vienna, Austria, I was struck by the abysmal outcomes and quality of life experienced by the patients for whom I cared. I was equally struck by the absence of quality evidence that would guide us in our treatment of these vulnerable patients. Seeking to make a difference, I sought and underwent doctoral training in health policy and epidemiology at Harvard, with the career goal to conduct high quality research that would fill important evidence gaps in our field. At Brigham and Womens Hospital, I joined the Division of Pharmacoepidemiology where I learned from some of the leaders in the field how to conduct quality comparative effectiveness research long before it became a buzz-word. My immediate colleagues and the wider environment at Harvard Medical School enabled me to master and apply the most novel analytical approaches that are necessary to tackle difficult problems in the presence of confounding by indication, a dreaded threat to validity in comparative effectiveness research. I was able to build a group of colleagues that shared a passion for drug utilization and comparative effectiveness research in kidney disease, cardiovascular disease, and diabetes, and we were able to publish our findings in leading journals.
Having recently moved to Stanford, I am in the process of building a young research group that will again focus on comparative effectiveness research. Here, I am once again in the privileged position to build on a fabulous research environment and an exquisite wealth of knowledge and experience represented by the scientists and clinicians on and off campus. With the enthusiastic support and collaborations of my colleagues here at Stanford as well as at other institutions in the U.S. and Europe, I am confident that we will provide important contributions that will guide us towards more evidence based and effective care of our patients with kidney disease. Doing so will hopefully contribute to improving the lives of these vulnerable patients, which is my explicit career goal.